Mendelian Randomization Analysis of Circulating Cytokines and Risk of Autoimmune Neuroinflammatory Diseases

References

• Zhou ZJ, Xia P. Elevated levels of NLRP3 inflammasome in serum of patients with chronic inflammatory demyelinating polyradiculoneuropathy are associated with disease severity. Neurol Sci. 2021;42(8):3383–3387. doi:10.1007/s10072-020-04949-7
   PubMed Web of Science ®Google Scholar
• Sangsefidi S, Ghafouri-Fard S, Komaki A, et al. High Levels of Il-19 in Patients with Chronic Inflammatory Demyelinating Polyneuropathy. J Mol Neurosci. 2020;70(12):1997–2000. doi:10.1007/s12031-020-01602-y
   PubMed Web of Science ®Google Scholar
• Danikowski KM, Jayaraman S, Prabhakar BS. Regulatory T cells in multiple sclerosis and myasthenia gravis. J Neuroinflammation. 2017;14(1):117. doi:10.1186/s12974-017-0892-8
   PubMed Web of Science ®Google Scholar
• Boyko EJ. Observational research--opportunities and limitations. J Diabetes Complications. 2013;27(6):642–648. doi:10.1016/j.jdiacomp.2013.07.007
   PubMed Web of Science ®Google Scholar
• Smith GD, Ebrahim S. ‘Mendelian randomization’: can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol. 2003;32(1):1–22. doi:10.1093/ije/dyg070
   PubMed Web of Science ®Google Scholar
• Zheng J, Baird D, Borges MC, et al. Recent Developments in Mendelian Randomization Studies. Curr Epidemiol Rep. 2017;4(4):330–345. doi:10.1007/s40471-017-0128-6
   PubMedGoogle Scholar
• Vandebergh M, Becelaere S, Dubois B, et al. Body mass index, interleukin-6 signaling and multiple sclerosis: a Mendelian randomization study. Front Immunol. 2022;13:834644. doi:10.3389/fimmu.2022.834644
   PubMed Web of Science ®Google Scholar
• Lu H, Wu PF, Zhang W, et al. Circulating interleukins and risk of multiple sclerosis: a Mendelian randomization study. Front Immunol. 2021;12:647588. doi:10.3389/fimmu.2021.647588
   PubMed Web of Science ®Google Scholar
• Lu H, Wu PF, Ma DL, et al. Growth factors and their roles in multiple sclerosis risk. Front Immunol. 2021;12:768682. doi:10.3389/fimmu.2021.768682
   PubMedGoogle Scholar
• Ahola-Olli AV, Würtz P, Havulinna AS, et al. Genome-wide association study identifies 27 loci influencing concentrations of circulating cytokines and growth factors. Am J Hum Genet. 2017;100(1):40–50. doi:10.1016/j.ajhg.2016.11.007
   PubMed Web of Science ®Google Scholar
• International Multiple Sclerosis Genetics Consortium*† and ANZgene and IIBDGC and WTCCC2. Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility. Science. 2019;365(6460):eaav7188.
   PubMed Web of Science ®Google Scholar
• Estrada K, Whelan CW, Zhao F, et al. A whole-genome sequence study identifies genetic risk factors for neuromyelitis optica. Nat Commun. 2018;9(1):1929. doi:10.1038/s41467-018-04332-3
   PubMedGoogle Scholar
• Jiang L, Zheng Z, Fang H, et al. A generalized linear mixed model association tool for biobank-scale data. Nat Genet. 2021;53(11):1616–1621. doi:10.1038/s41588-021-00954-4
   PubMed Web of Science ®Google Scholar
• Verbanck M, Chen CY, Neale B, et al. Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. Nat Genet. 2018;50(5):693–698. doi:10.1038/s41588-018-0099-7
   PubMed Web of Science ®Google Scholar
• Greco MF, Minelli C, Sheehan NA, et al. Detecting pleiotropy in Mendelian randomisation studies with summary data and a continuous outcome. Stat Med. 2015;34(21):2926–2940. doi:10.1002/sim.6522
   PubMed Web of Science ®Google Scholar
• Sekula P, Del Greco MF, Pattaro C, et al. Mendelian Randomization as an Approach to Assess Causality Using Observational Data. J Am Soc Nephrol. 2016;27(11):3253–3265. doi:10.1681/ASN.2016010098
   PubMed Web of Science ®Google Scholar
• Sedgwick P. Multiple hypothesis testing and Bonferroni’s correction. BMJ. 2014;349(oct20 3):g6284. doi:10.1136/bmj.g6284
   PubMedGoogle Scholar
• Maier LM, Anderson DE, Severson CA, et al. Soluble IL-2RA levels in multiple sclerosis subjects and the effect of soluble IL-2RA on immune responses. J Immunol. 2009;182(3):1541–1547. doi:10.4049/jimmunol.182.3.1541
   PubMed Web of Science ®Google Scholar
• Greenberg SJ, Marcon L, Hurwitz BJ, et al. Elevated levels of soluble interleukin-2 receptors in multiple sclerosis. N Engl J Med. 1988;319(15):1019–1020.
   PubMedGoogle Scholar
• Gallo P, Piccinno MG, Pagni S, et al. Immune activation in multiple sclerosis: study of IL-2, sIL-2R, and gamma-IFN levels in serum and cerebrospinal fluid. J Neurol Sci. 1989;92(1):9–15. doi:10.1016/0022-510X(89)90171-8
   PubMed Web of Science ®Google Scholar
• Khaibullin T, Ivanova V, Martynova E, et al. Elevated Levels of Proinflammatory Cytokines in Cerebrospinal Fluid of Multiple Sclerosis Patients. Front Immunol. 2017;8:531. doi:10.3389/fimmu.2017.00531
   PubMed Web of Science ®Google Scholar
• Malek TR, Bayer AL. Tolerance, not immunity, crucially depends on IL-2. Nat Rev Immunol. 2004;4(9):665–674. doi:10.1038/nri1435
   PubMed Web of Science ®Google Scholar
• Field J, Fox A, Jordan MA, et al. Interleukin-2 receptor-α proximal promoter hypomethylation is associated with multiple sclerosis. Genes Immun. 2017;18(2):59–66. doi:10.1038/gene.2016.50
   PubMed Web of Science ®Google Scholar
• Matejčíková Z, Mareš J, Sládková V, et al. Cerebrospinal fluid and serum levels of interleukin-8 in patients with multiple sclerosis and its correlation with Q-albumin. Mult Scler Relat Disord. 2017;14:12–15. doi:10.1016/j.msard.2017.03.007
   PubMed Web of Science ®Google Scholar
• Lund BT, Ashikian N, Ta HQ, et al. Increased CXCL8 (IL-8) expression in multiple sclerosis. J Neuroimmunol. 2004;155(1–2):161–171. doi:10.1016/j.jneuroim.2004.06.008
   PubMed Web of Science ®Google Scholar
• Ortega SB, Kashi VP, Tyler AF, et al. The disease-ameliorating function of autoregulatory CD8 T cells is mediated by targeting of encephalitogenic CD4 T cells in experimental autoimmune encephalomyelitis. J Immunol. 2013;191(1):117–126. doi:10.4049/jimmunol.1300452
   PubMed Web of Science ®Google Scholar
• Vazirinejad R, Ahmadi Z, Kazemi Arababadi M, et al. The biological functions, structure and sources of CXCL10 and its outstanding part in the pathophysiology of multiple sclerosis. Neuroimmunomodulation. 2014;21(6):322–330. doi:10.1159/000357780
   PubMed Web of Science ®Google Scholar
• Balashov KE, Rottman JB, Weiner HL, et al. CCR5 + and CXCR3 + T cells are increased in multiple sclerosis and their ligands MIP-1α and IP-10 are expressed in demyelinating brain lesions. Proc Natl Acad Sci U S A. 1999;96(12):6873–6878. doi:10.1073/pnas.96.12.6873
   PubMed Web of Science ®Google Scholar
• Sørensen TL, Trebst C, Kivisäkk P, et al. Multiple sclerosis: a study of CXCL10 and CXCR3 co-localization in the inflamed central nervous system. J Neuroimmunol. 2002;127(1–2):59–68. doi:10.1016/S0165-5728(02)00097-8
   PubMed Web of Science ®Google Scholar
• Beppu M, Sawai S, Misawa S, et al. Serum cytokine and chemokine profiles in patients with chronic inflammatory demyelinating polyneuropathy. J Neuroimmunol. 2015;279:7–10. doi:10.1016/j.jneuroim.2014.12.017
   PubMed Web of Science ®Google Scholar
• Dziadkowiak E, Moreira H, Wieczorek M, et al. Correlations between electrophysiological parameters, lymphocyte distribution and cytokine levels in patients with chronic demyelinating inflammatory polyneuropathy. J Pers Med. 2021;11(8):766. doi:10.3390/jpm11080766
   PubMed Web of Science ®Google Scholar
• Castellino F, Huang AY, Altan-Bonnet G, et al. Chemokines enhance immunity by guiding naive CD8+ T cells to sites of CD4+ T cell-dendritic cell interaction. Nature. 2006;440(7086):890–895. doi:10.1038/nature04651
   PubMed Web of Science ®Google Scholar
• Ramesh G, MacLean AG, Philipp MT. Cytokines and chemokines at the crossroads of neuroinflammation, neurodegeneration, and neuropathic pain. Mediators Inflamm. 2013;2013:480739. doi:10.1155/2013/480739
   PubMed Web of Science ®Google Scholar
• Khan AW, Farooq M, Hwang MJ, et al. Autoimmune neuroinflammatory diseases: role of interleukins. Int J Mol Sci. 2023;24(9):7960. doi:10.3390/ijms24097960
   PubMed Web of Science ®Google Scholar
• Du L, Chang H, Xu W, et al. Elevated chemokines and cytokines for eosinophils in neuromyelitis optica spectrum disorders. Mult Scler Relat Disord. 2021;52:102940. doi:10.1016/j.msard.2021.102940
   PubMed Web of Science ®Google Scholar
• Yang X, Peng J, Huang X, et al. Association of circulating follicular helper T Cells and Serum CXCL13 With neuromyelitis optica spectrum disorders. Front Immunol. 2021;12:677190. doi:10.3389/fimmu.2021.677190
   PubMed Web of Science ®Google Scholar
• Uzawa A, Kawaguchi N, Himuro K, et al. Serum cytokine and chemokine profiles in patients with myasthenia gravis. Clin Exp Immunol. 2014;176(2):232–237. doi:10.1111/cei.12272
   PubMed Web of Science ®Google Scholar
• Huan X, Zhao R, Song J, et al. Increased serum IL-2, IL-4, IL-5 and IL-12p70 levels in AChR subtype generalized myasthenia gravis. BMC Immunol. 2022;23(1):26. doi:10.1186/s12865-022-00501-8
   PubMed Web of Science ®Google Scholar
• Wang L, Zhang Y, Zhu M, et al. Effects of follicular helper t cells and inflammatory cytokines on myasthenia gravis. Curr Mol Med. 2019;19(10):739–745. doi:10.2174/1566524019666190827162615
   PubMed Web of Science ®Google Scholar